

Phenotypic Identification and Detection of *Bla*CTX and *Tet*M in *Klebsiella* species from Urine Samples of Patients in Ile-Ife, Nigeria

Abstract

Klebsiella species from urine samples patients in Ile-Ife were investigated. Isolation, characterization and identification of the isolates were done using standard microbiological techniques. Antibiotic sensitivity of the *Klebsiella* isolates to twelve different antibiotics was determined by Kirby-Bauer's disc diffusion method on Mueller-Hinton agar plates. Plasmid DNA in representative multiple antibiotic resistant isolates was detected by alkaline lysis (TENS buffer). Resistance (*bla* CTX, *tet* M) genes were detected by Polymerase Chain Reaction (PCR). Statistical analysis of data obtained was done using SPSS-17.0. A total of thirty-two *Klebsiella* sp. (7.02%) were isolated from 456 urine samples of patients; 50 urine samples collected from apparently healthy individuals served as control. Antibiotic resistance was high and also varied among the isolates with a range of 37.5% to 100%. Most of the isolates had multiple antibiotic resistance (MAR) to at least three different classes of antibiotics. There was diversity in the MAR patterns with 21 different antibiotypes which ranged from two to ten different antibiotics. Plasmid DNA of molecular weight of 900 bp to 9416 bp was detected in some representative multiple antibiotic resistant isolates. Three isolates harboured *bla* CTX (543 bp) gene which codes for resistance to beta-lactams. However, *tet* M (974 bp) gene which codes for resistance to tetracycline was not detected in any of the isolates. The study concluded that there were multiple antibiotic resistant *Klebsiella* species from urine samples of patients which harboured plasmid DNA and resistance (*bla* CTX) gene which is of great health and economic consequences.

Keywords: *Klebsiella* species, urine, in-patients and out-patients, multiple antibiotic resistance, resistance genes

1. Introduction

Klebsiella species are pathogens found as members of the normal intestinal flora of humans and animals and may be isolated from a variety of environmental sources, on the hands of hospital personnels with the principal pathogenic reservoirs being the gastrointestinal tract of humans (Brisse *et al.*, 2006). *Klebsiella* species is an important nosocomial microorganism which may cause high rate of fatality in hospital settings, affecting different age groups and sexes (Nordamann *et al.*, 2009). It was reported as the most prevalent uropathogen causing asymptomatic bacteriuria in some out-patients attending various clinics at the University of Benin teaching hospital in Benin City, Nigeria (Osazuwa *et al.*, 2010). *Klebsiella pneumoniae* is the most common species isolated from hospital patients.

Under normal circumstances the kidney, ureter and the urinary bladder of mammals are sterile. Urine within the urinary bladder is also sterile. However, in both males and females, a few bacteria are usually present in the distal portion of the urethra (Geoffrey *et al.*, 2013). Infections of the urinary tract are one of the most common infectious diseases (Kolawale *et al.*, 2009; Delanghe *et al.*, 2000; Hryniewicz *et al.*, 2001;).

Nosocomial infections occur worldwide, both in the developed and developing countries. More recently, hospital acquired infections (HAIs) have been shown to be a significant economic burden to patients and public health in developing countries (Nyamogoba and Obala, 2002; Rossello-Urgell, 2004). Colonized patients have a higher risk of nosocomial infection than patients who are not colonized (Koenig and Truwit, 2006). A variety of vehicles have been implicated in the spread of nosocomial pathogens (Samuel *et al.*, 2010). In most of the patients, a variety of sites are colonized, mostly the urinary tract, with or without a serious infection (Dhingra, 2008). In a hospital based patient survey in Saudi Arabia, 38 (33.3%) patients had hospital acquired infection (Hanan *et al.*, 2006), 6.7% was recorded among patients on admission in a study in Ghana (Newman, 2009).

Statistical data and evidences from researches prove that multidrug resistant bacteria are emerging worldwide which is a big challenge to healthcare. Multidrug resistant bacteria cause serious nosocomial and community acquired infections that are hard to eradicate using available antibiotics (Archana and Harsh, 2011). Extensive use of broad-spectrum antibiotics in hospitalized patients has led to both increased carriage of *Klebsiella* and the development of multidrug resistant strains that produce extended-spectrum beta-lactamase (ESBL) (Archana and Harsh, 2011; Sachse *et al.*, 2014). *Klebsiella* isolates have steadily increased over the past years and they have been important sources of transferable antibiotic resistance (Shah *et al.*, 2010). For instance, the prevalent pathogens of UTIs have been found to be resistant to most chemotherapeutic agents (Okonko *et al.*, 2009b).

The epidemiology of nosocomial outbreaks can be more complex when the resistance is mediated by several mechanisms the important one of which is the production of enzymes encoded by several genes that are carried on some bacterial plasmids (Karim *et al.*, 2001). Plasmids that carry several different resistance genes can confer resistance to multiple antibacterial agents (Chen *et al.*, 2014a). *Klebsiella* species contain many plasmids that differ in number and molecular weight, carrying different types of genes including those encoding extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases and inhibitor resistant TEM beta-lactamases. These enzymes confer resistance to various antimicrobial agents including third and fourth generation cephalosporins, cephamycins, beta-lactamase/inhibitor combinations and carbapenems (Essack *et al.*, 2004). The number of resistance genes carried on the plasmids of multidrug resistant *Klebsiella pneumoniae* is usually more than one and occasionally as many as five genes are reported (Poirel *et al.*, 2004).

Indiscriminate use of third generation cephalosporins to treat Gram-negative bacterial infections is partly responsible for the emergence of resistance to beta-lactams (Shah *et al.*, 2010). *Klebsiella pneumoniae* is at the forefront of antimicrobial resistance for Gram-negative

pathogenic bacteria, as strains resistant to third-generation cephalosporins and carbapenems are widely reported. The worldwide diffusion of these strains is of great concern, due to the high morbidity and mortality often associated with *Klebsiella pneumoniae* infections in hospital environments (Gaiarsa *et al.*, 2015). In a study, resistance was observed to aminoglycosides, fluoroquinolones, chloramphenicol, and co-trimoxazole, genes encoding TEM, SHV, CTX-M, OXA-2, and AmpC types of beta-lactamases in the *Escherichia coli*, *Klebsiella* species and *Enterobacter* species isolates were also detected (Priamchuk *et al.*, 2010).

Antibiotic resistance is a large and growing problem in the microbial world that accounts for most of Africa's disease burden (Okeke *et al.*, 2007). Many factors play in the emergence of antibiotic resistant bacteria (WHO, 2012) from poor utilization of antimicrobial agents, to the transmission of resistant bacteria from patient to patient, from healthcare workers to patients and vice versa, to a lack of guidelines for appropriate and judicious use of antimicrobial agents.

2. Materials and Methods

2.1 Study population, sampling and bacteriological analysis

Voided mid-stream urine samples were collected into sterile labelled universal bottles from in-patients (patients admitted into the hospital) and out-patients (patients who come to the hospital daily) in Obafemi Awolowo University Teaching Hospitals Complex and Obafemi Awolowo University Health Centre, Ile-Ife, Nigeria. The samples were collected after ethical clearance and informed consent were obtained. The subjects were educated to collect midstream urine specimen into sterile wide-mouthed capped universal bottles. The samples were transported in ice pack (4°C) to the laboratory for analysis. Preliminary identification of the isolates was based on phenotypic characteristics on MacConkey agar plates. The identity of the isolates was further confirmed by various biochemical tests following Bergey's Manual of Determinative Bacteriology (Breed *et al.*, 1957).

2.2 Antibiotic susceptibility testing

Antibiotic susceptibility of the isolates was tested by Kirby-Bauer's disc diffusion method using the following antibiotics: cotrimoxazole (30 µg), chloramphenicol (30 µg), ciprofloxacin (10 µg), amoxicillin (30 µg), amoxicillin-clavulanic acid (30 µg), gentamycin (10 µg), pefloxacin (30 µg), ofloxacin (10 µg), streptomycin (30 µg), ceftriaxone (30 µg), nitrofurantoin (200 µg) and tetracycline (30 µg). Broth culture of the isolates was standardized by comparing its turbidity to that of 0.5 McFarland standard and subsequently seeded on sterile Mueller-Hinton agar plates. The antibiotic discs were aseptically placed on the inoculated Mueller-Hinton agar plates using sterile forceps. The plates were incubated in an inverted position at 37°C for 18-24 h. The diameter of the zones of inhibition were measured to the nearest millimetre and compared to the zone diameter interpretative chart of the Clinical and Laboratory Standards Institute (CLSI, 2013).

2.3 Plasmid Profiling

Plasmid DNA of the representative multiple antibiotic resistant *Klebsiella* isolates were extracted using TENS (25 mM Tris, 10 mM EDTA, 0.1 N NaOH and 0.5% SDS- Sigma products) buffer. The plasmid DNA was separated by electrophoresis using 0.8% agarose gel (Oxoid, England) in Tris-acetate-EDTA buffer (10 ml of 50X TAE per 1000 ml of sterile distilled water) and ethidium bromide (10 mg/ml), a Lambda DNA/HindIII Marker, 2 (Fermentas, USA) was used as standard. The plasmid DNA bands were visualized under ultraviolet transilluminator and compared to the reference marker.

2.4 Detection of *bla* CTX and *tet M* genes in *Klebsiella* species

Deoxyribonucleic acid of representative multiple antibiotic resistant *Klebsiella* isolates was extracted by boiling. The sequences of the forward and reverse primers used are represented in Table 1. Polymerase chain reaction (PCR) was performed in 20 µl reaction mixtures which contained 11 µg/ml of the DNA template (total DNA of bacteria), 4.0 µl of the master mix (Solis Biodyne, Estonia), 0.2 µl each of the forward and reverse primers, and sterile distilled water was added to make a final volume of 20 µl. The mixture was vortexed and amplified in a thermocycler. The thermocycler was programmed as follows: an initial denaturation step at 95°C for 5 minutes, 35 cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for *bla*CTX, 57°C for *tetM* for 1 minute, extension at 72°C for 90 seconds, a final extension step at 72°C for 10 minutes and a final hold at 4°C. The amplified PCR products were separated by electrophoresis using 1.5% agarose gel (Oxoid, England) in Tris-acetate-EDTA (10 ml of 50X TAE per 1000 ml of sterile distilled water) buffer and ethidium bromide (10 mg/ml). A 100 bp DNA marker (Solis Biodyne, Estonia) was used as a standard. The gel was visualised under ultraviolet transilluminator and the fragment size compared to that of the standard.

Table 1. Primers used in the detection of resistance (*bla*CTX (543 bp), *tetM* (974 bp) genes.

Primer	Sequence	Reference
<i>bla</i> CTX (forward)	5'-ATGTGCAGYACCAGTAARGTKATGGC-3'	Jemima & Verghese, 2008
<i>bla</i> CTX (reverse)	5'-TGGGTRAARTARGTSACCAGAAYCAGCGG-3'	
<i>tetM</i> (forward)	5'-CGAACAAGAGGAAAGCATAAG-3'	Li and Wang, 2010.
<i>tetM</i> (reverse)	5'-CAATACAATAGGAGCAAGC-3'	

3. Results

A total of thirty-two *Klebsiella* species were isolated from 456 urine samples of in-patients and out-patients collected. These include nineteen and thirteen *Klebsiella* isolates from in-patients

and out-patients, respectively. These isolates comprised *Klebsiella pneumoniae* (59.4%), *Klebsiella ozaenae* (28.1%) and *Klebsiella oxytoca* (12.5%). Antibiotic resistance was high and varied among the isolates. Most of the isolates were resistant to amoxicillin-clavulanic acid (93.75%), tetracycline (71.88%) and ciprofloxacin (31.25%) being the least.

The multiple antibiotic resistant (MAR) isolates were described as being resistant to three or more different classes of antibiotics. There was diversity in the MAR pattern with 21 different antibiotypes which ranged from two to eleven different antibiotics. This consists of *Klebsiella pneumoniae* (59.4%), *Klebsiella ozaenae* (28.1%) and *Klebsiella oxytoca* (12.5%). The most prevalent antibiotype (C CIP AMC CN COT TE NIT) was expressed in *Klebsiella pneumoniae*, *Klebsiella ozaenae* and *Klebsiella oxytoca* isolated from urine samples of both in- and out-patients, and were resistant to all the antibiotics tested. The MAR patterns of the isolates are represented in Tables 3a and 3b.

Table 2. Percentage antibiotic susceptibilities of *Klebsiella* sp. from urine samples of in-patients and out-patients.

Antibiotics (µg)	Number of isolates (n)	Percentage (n%)		
		Susceptibility	Intermediate	Resistant
Chloramphenicol (30 µg)	32	37.50	18.75	43.75
Ciprofloxacin (10 µg)	32	53.13	15.63	31.25
Amoxicillin (30 µg)	32	12.50	25.00	62.50
Amoxicillin-Clavulanic acid (30 µg)	32	0.00	6.25	93.75
Gentamycin (10 µg)	32	62.50	3.13	34.38
Ofloxacin (10 µg)	32	62.50	6.25	31.25
Streptomycin (30 µg)	32	46.88	12.50	40.63
Nitrofurantoin (200 µg)	32	0.00	0.00	100.00
Cotrimoxazole (25 µg)	32	34.38	18.75	46.88
Tetracycline (30 µg)	32	6.25	21.88	71.88
Ceftriaxone (30 µg)	32	3.13	28.13	68.75

Table 3a. Multiple antibiotic resistance profile of *Klebsiella* sp. from urine samples of inpatients.

Isolates	Number of antibiotic classes	MAR patterns	Frequency n	n%
<i>Klebsiella pneumoniae</i>	3	AMC CN NIT	1	0.0625
		AUC TE NIT	1	0.0625
		CRO TE NIT	1	0.0625
	4	AMC CN TE NIT	1	0.0625
		C AMC TE NIT	1	0.0625
	5	C AMC CN TE NIT	1	0.0625
	7	C CIP AMC CN COT TE NIT	1	0.0625
		C CIP CRO CN COT TE NIT	1	0.0625
<i>Klebsiella ozaenae</i>	3	AMC TE NIT	1	0.0625
	4	C AMC COT NIT	1	0.0625
	6	C AMC CN COT TE NIT	1	0.0625
		CIP AMC CN COT TE NIT	1	0.0625
		C CIP AMC CN COT TE NIT	1	0.0625
	7	C CIP AMC S COT TE NIT	1	0.0625
		C CIP CRO S COT TE NIT	1	0.0625
<i>Klebsiella oxytoca</i>	3	AMC TE NIT	1	0.0625
Total			16	

Key: C-Chloramphenicol, AMC-Amoxicillin-Clavulanic acid, AMX-Amoxicillin, CRO-Ceftriaxone, CIP-Ciprofloxacin, CN-Gentamycin, S-Streptomycin, TE-Tetracycline, COT-Cotrimoxazole, NIT-Nitrofurantoin.

Table 3b. Multiple antibiotic resistance profile of *Klebsiella* sp. from urine samples of out-patients.

Isolates	Number of	MAR patterns	Frequency (n%)	
antibiotic classes			n	
<i>Klebsiella</i>	3	AMC TE NIT	2	0.2
<i>pneumoniae</i>	5	CIP AMC COT TE NIT	1	0.1
	6	C AMC S COT TE NIT	1	0.1
	7	C CIP AMC CN COT TE NIT	1	0.1
<i>Klebsiella ozaenae</i>	5	C AMC CN COT NIT	1	0.1
	7	C CIP AMC S COT TE NIT	1	0.1
<i>Klebsiella oxytoca</i>	3	CRO TE NIT	1	0.1
	5	AMC S COT TE NIT	1	0.1
	7	C CIP AMC CN COT TE NIT	1	0.1
		Total	10	

Key: C-Chloramphenicol, AMC-Amoxicillin-Clavulanic acid, AMX-Amoxicillin, CRO-Ceftriaxone, CIP-Ciprofloxacin, CN-Gentamycin, S-Streptomycin, TE-Tetracycline, COT-Cotrimoxazole, NIT-Nitrofurantoin.

The molecular weight of the plasmid DNA ranged from 900 to 9416 bp. However, *Klebsiella pneumoniae* from urine samples of in-patients had a multiple plasmid DNA with molecular weight of 900, 6557 and 9416 bp. *Klebsiella ozaenae* and *Klebsiella pneumoniae* from urine samples of out-patients also harboured multiple plasmid DNA of molecular weight ranging from 900 to 9416 bp. The agarose gel electrophoresis of plasmid DNA in the MAR *Klebsiella* isolates is represented in Plate 1. Tables 4a and 4b show the molecular weight of the plasmid DNA.



Plate 1. Plasmid profile of MAR *Klebsiella* sp. from urine samples of in-patients and out-patients.

Lane M = Lambda DNA/HindIII Marker, 2, Lane N = Negative control, Lane 1-5 (K402, K391-UTI, K95-Fibroid in pregnancy, K84, K108-?UTI) = *Klebsiella pneumoniae*, Lane 6 (K85) = *Klebsiella oxytoca*, Lane 7 (K151) = *Klebsiella ozaenae*, Lane 8, 9 (K326-?UTI, K37) = *Klebsiella pneumoniae*, Lane 10, 11 (K14, K339-Bladder outlet obstruction) = *Klebsiella ozaenae*, Lane 12, 13 (K152, K88-Hypertension) = *Klebsiella pneumoniae*, Lane 14 (K272-Hypertension) = *Klebsiella ozaenae*, Lane 15 (K301-Benign prostate enlargement) = *Klebsiella pneumoniae*, Lane 16 (K105-UTI) = *Klebsiella ozaenae*, Lane 17 (K158) = *Klebsiella pneumoniae*, Lane 18 (K255-Urethral stricture) = *Klebsiella oxytoca*.

Table 4a. Molecular weight of plasmid DNA in MAR *Klebsiella* sp. from urine samples of in-patients.

Lanes/Isolates	Number of Plasmids	Molecular Weight (bp)	MAR Patterns
L1=402	1	9416	AMC TE NIT
L2=391	1	9416	AMC CN NIT
L3=95	-	-	CRO TE NIT
L4=84	1	9416	C CIP AMC CN
			COT TE NIT
L8=326	3	9416, 6557, 900	AMC CN TE NIT
L11=339	1	9416	CIP AMC CN COT
			TE NIT
L13=88	1	9416	C AMC TE NIT
L14=272	1	9416	C CIP AMC S COT
			TE NIT
L15=301	1	9416	C AMC CN TE NIT
L16=105	1	9416	CH CIP CRO S COT
			TE NIT
L18=255	1	9416	AMC TE NIT

Key: L1-L4, L8, L12, L13, L15 = *Klebsiella pneumoniae*, L11, L14, L16 = *Klebsiella ozaenae*, L18 = *Klebsiella oxytoca*, C-Chloramphenicol, AMC-Amoxicillin-Clavulanic acid, CRO-Ceftriaxone, CIP-Ciprofloxacin, CN-Gentamycin, S-Streptomycin, TE-Tetracycline, COT-Cotrimoxazole, NIT-Nitrofurantoin.

Table 4b. Molecular weight of plasmid DNA in MAR *Klebsiella* sp. from urine samples of out-patients.

	Lanes/Isolates	Number of Plasmids	Molecular Weight (bp)	MAR Patterns
265	L5=108	-	-	AMC TE NIT
266	L6=85	2	9416, 4361	AMC S COT TE
267				NIT
268	L7=151	3	9416, 4361,900	C CIP AMC S
269				COT TE NIT
270	L9=37	-	-	C AMC S COT
271				TE NIT
272	L10=14	-	-	C AMC CN COT
273				NIT
274	L12=152	1	9416	CIP AMC COT TE
275				NIT
276	L17=158	1	9416	AMC TE NIT

277 Key: L5, L9, L12, L17 = *Klebsiella pneumoniae*, L6= *Klebsiella oxytoca*, L7, L10 = *Klebsiella*
278 *ozaenae*, C-Chloramphenicol, AMC-Amoxicillin-Clavulanic acid, CRO-Ceftriaxone, CIP-
279 Ciprofloxacin, CN-Gentamycin, S-Streptomycin, TE-Tetracycline, COT-Cotrimoxazole, NIT-
280 Nitrofurantoin.

281
282 *Klebsiella pneumoniae* (2) and *Klebsiella ozaenae* (1) from urine samples of in-patients
283 harboured *bla*CTX (543 bp) gene coding for resistance to beta-lactams, respectively as depicted
284 by Lanes 4, 11 and 15. However, none of the selected MAR *Klebsiella* isolates harboured *tetM*
285 (974) gene. These results are shown in Plates 2a and 2b.

286



Plate 2a. Agarose gel electrophoresis of the amplification products coding *bla*CTX (543 bp) gene in MAR *Klebsiella* sp. from urine samples of in-patients and out-patients.

Lane M = 100 bp DNA Marker, Lane N = Negative control, Lane 1-5 (K402, K391-UTI, K95-Fibroid in pregnancy, K84, K108-?UTI) = *Klebsiella pneumoniae*, Lane 6 (K85) = *Klebsiella oxytoca*, Lane 7 (K151) = *Klebsiella ozaenae*, Lane 8, 9 (K326-?UTI, K37) = *Klebsiella pneumoniae*, Lane 10, 11 (K14, K339-Bladder outlet obstruction) = *Klebsiella ozaenae*, Lane 12, 13 (K152, K88-Hypertension) = *Klebsiella pneumoniae*, Lane 14 (K272-Hypertension) = *Klebsiella ozaenae*, Lane 15 (K301-Benign prostate enlargement) = *Klebsiella pneumoniae*, Lane 16 (K105-UTI) = *Klebsiella ozaenae*, Lane 17 (K158) = *Klebsiella pneumoniae*, Lane 18 (K255-Urethral stricture) = *Klebsiella oxytoca*.

4. Discussion

The recovery of *Klebsiella* species (7.02%) from urine samples of in-patients and out-patients in the study area establishes the fact that *Klebsiella* sp. can be found in the urine of in-patients and out-patients presenting different clinical conditions, with *Klebsiella pneumoniae* (59.4%) predominating among the isolates. This is supported by other studies, though with higher prevalence such as 19.1% by Osundiya *et al.* (2013), 10.8% by Feglo *et al.* (2010) and 19.72%

by Akter *et al.* (2014) on the investigation of *Klebsiella* species in urine samples from in-patients and out-patients in Nigeria, Ghana and India, respectively. Hospital acquired infections (HAIs) have been shown to be of serious concern in patients and public health in developing countries. They are a major cause of death and increased morbidity in hospitalized patients. They may cause increased functional disability and emotional stress and may lead to conditions that reduce quality of life. Not only do they affect the general health of patients, but they are also a huge burden financially. The greatest contributors to these costs are the increased stays that patients with nosocomial infections require (WHO, 2002; Gastmeier, 2004). *Klebsiella* species commonly cause infections following intravenous and urinary catheterization, and infections complicating burns (Deirdre *et al.*, 2006). Individuals who are immunosuppressed by therapy (e.g. cancer patients or transplant recipients) or by congenital defects of the immune system may develop *Klebsiella* infections. Such infections often have lethal course (Abbas and Lichtman, 2010). The use of antibiotics can be a factor that increases the risk of nosocomial infection with *Klebsiella* sp. (Weinserberg *et al.*, 2009). Sepsis and septic shock can follow entry of the bacteria into the blood, and may lead to death (Dellinger *et al.*, 2008; Patel and Balk, 2012). High resistance to antibiotics was observed in most of the *Klebsiella* isolates. *Klebsiella* species have been reported to show high resistance rates to various antimicrobial agents including fluoroquinolones, tetracycline and beta-lactams (Okonko *et al.*, 2009a; Dashti *et al.*, 2010; Archana and Harsh, 2011; Orhue *et al.*, 2012; Olusola *et al.*, 2013; Nwosu *et al.*, 2014). *Klebsiella* isolates have been steadily increasing over the past years and they have been important sources of transferable antibiotic resistance (Shah *et al.*, 2010). Reports from multiple studies from different parts of Nigeria though have observed temporal trends in the prevalence of resistance among enteric organisms; they have shown increasing prevalence in the last fifteen years (Okeke *et al.*, 2000; Nwosu *et al.*, 2014). The misuse of antimicrobial agents accelerates this natural phenomenon that is antibiotic resistance (Nwosu *et al.*, 2014). Poor infection control practices also encourage the spread of antimicrobial resistance (AMR) (WHO, 2013). The percentage multiple antibiotic resistances are higher in isolates from urine samples of in-patients than out-patients, implying a high risk of nosocomial infection. These isolates were observed to have resistance to commonly used antibiotics in treating *Klebsiella* related infections. Extensive use of broad-spectrum antibiotics in hospitalized patients has led to both increased carriage of *Klebsiella* and the development of multidrug resistant strains that produce extended-spectrum beta-lactamase (ESBL) (Archana and Harsh, 2011; Sachse *et al.*, 2014).

The presence of plasmid DNA among the multiple antibiotic resistant *Klebsiella* isolates might have conferred antibiotic resistance in them. In hospital-acquired infections, for example, the same plasmid type may suggest single source of infection. The finding of multiple plasmid profiles may also suggest multiple sources of infection or endogenous infections. Plasmids that carry several different resistance genes can confer resistance to multiple antibacterial agents. Antibacterial resistance genes can be exchanged between different bacterial strains or species via plasmids that carry these resistance genes (Baker-Austin *et al.*, 2006; Alekshun and Levy, 2007; Chen *et al.*, 2014a). Plasmids have been found to confer drug resistance to their host bacteria by various mating processes such as conjugation (Lipps, 2008).

The presence of *bla*CTX (543 bp) gene in the isolates might have mediated resistance to the beta-lactam antibiotics. Increasing resistance to broad spectrum cephalosporins in *Klebsiella* species predominantly due to the production of ESBLs were reported from different countries (Khanfar *et al.*, 2009). The beta-lactamases produced by bacteria are known to protect them against the lethal effect of penicillins, cephalosporins and monobactams on their cell wall synthesis. The ESBL producing bacteria are increasingly causing urinary tract infections both in hospitalized and out-patients. This could make therapy of UTI difficult and promote greater use of expensive broad spectrum antibiotics, such as carbapenems (Mehrgan and Rahbar, 2008). Although *TetM* (974 bp) gene may be found in Gram-negative organisms, it was not detected in any of the MAR *Klebsiella* isolates represented. The *Klebsiella* isolates in this study may have other mechanisms of resistance or resistance genes (*tetK*, *tetA*, *tetO* etc.) through which resistance to tetracycline was conferred; there may be a need for further investigation. The MAR *Klebsiella* isolates harbouring plasmid DNA and resistance gene were from in- and out-patients suffering from UTI, fibroid in pregnancy, diabetes, hypertension, urethral stricture, bladder outlet obstruction and benign prostate enlargement. This implies a high risk of nosocomial infection that may pose serious health threat; these highly resistant strains may raise difficult therapeutic options and clinical problems.

5. Conclusion

This study showed the presence of multiple antibiotic resistant *Klebsiella* species harbouring plasmid DNA and resistance *bla*CTX (543 bp) gene in the study area that could be transferred from one patient to the other or to health care providers and vice versa especially when basic infection control measures are not taken. This is very important in the pathogenesis of community and hospital acquired infections. Promoting rational use of antibiotics and proper patient care, enhancing infection prevention and control in health care settings and fostering innovation, research and development are ways to overcome multiple antibiotic resistance problems.

Limitation

During this study, there was restriction in sample collection as patients who did not give their consent were exempted.

References

- Abbas AK and Lichtman AH. Basic Immunology: Functions and Disorders of the Immune System, Third Edition. Elsevier Health Sciences, 2010. ISBN 1437726755, 9781437726756.
- Akter J, Chowdhury AMM and Al Forkan M. Study on Prevalence and Antibiotic Resistance Pattern of *Klebsiella* Isolated from Clinical Samples in South East Region of Bangladesh. American Journal of Drug Discovery and Development. 2014;4:73-79.

382 Alekshun MN and Levy SB. Molecular mechanisms of antibacterial multidrug resistance. *Cell*.
383 2007;128(6):1037-50.

384 Archana SS and Harsh VB. Challenge to healthcare: Multidrug resistance in *Klebsiella*
385 *pneumoniae*. International Conference on Food Engineering and Biotechnology. 2011 IPCBEE
386 vol. 9, IACSIT Press, Singapore.

387 Baker-Austin C, Wright MS, Stepanauskas R and McArthur JV. Co-selection of antibiotic and
388 metal resistance. *Trends in Microbiology*. 2006;14(4): 176-82.

389 Breed RS, Murray EGD and Smith NR. *Bergey's Manual of Determinative Bacteriology*,
390 Seventh Edition, Copyright ©, 1957, The Williams & Wilkins Company, Composed and Printed
391 at the Waverly Press, Inc. Mt. Royal and Guilford Aves. Baltimore 2, Md., United States of
392 America. 1957.

393

394 Brisse S, Grimont F, and Grimont P. *Prokaryotes*. New York, NY: Springer, New York.
395 2006;159-196.

396 Chen Z, Wang Y, Tian L, Zhu X, Li L, Zhang B, Yan S. and Sun Z. First Report in China of
397 Enterobacteriaceae Clinical Isolates Coharboring blaNDM-1 and blaIMP-4 Drug Resistance
398 Genes. *Journal of Microbial Drug Resistance*. 2014.

399 Clinical and Laboratory Standards Institute (2013). Performance Standards for Antimicrobial
400 Susceptibility Testing; Twenty-third Informational Supplement. CLSI Document M100-S23.
401 Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne,
402 Pennsylvania, 19087, USA. 2014;33(1).

403 Dashti AA, Jadaon MM, Gomaa HH, Noronha B. and Udo EE. Transmission of a *Klebsiella*
404 *pneumoniae* clone harbouring genes for CTX-M-15-like and SHV-112 enzymes in a neonatal
405 intensive care unit of a Kuwaiti hospital. *Journal of Medical Microbiology*. 2010;59:687-692.

406 Delanghe JR, Kouri TT and Huber AR. The role of automated urine particle flow cytometry in
407 clinical practice. *Clinica Chimica Acta*. 2000;301(1-2): 1-18.

408 Dellinger RP, Levy MM, Carlet JM, Bion J and Parker MM. Surviving Sepsis Campaign:
409 international guidelines for management of severe sepsis and septic shock. *Journal of Intensive*
410 *Care Medicine*. 2008;34(1):17-60.

411 Deirdre C, Sameer E, Owen R, Brent W. and Robert L. Burn Wound Infections. *Journal of*
412 *Clinical Microbiology Reviews*. 2006;19(2): 403-434.

413 Dhingra KR. A Case of Complicated Urinary Tract Infection: *Klebsiella pneumoniae*
414 Emphysematous Cystitis Presenting as Abdominal Pain in the Emergency Department. *Western*
415 *Journal of Emergency Medicine*. 2008;9(3):171-173.

416 Essack SY, Hall LM and Livermore DM. *Klebsiella pneumoniae* isolate from South Africa with
417 multiple TEM, SHV and AmpC beta-lactamases. *International Journal of Antimicrobial Agents*.
418 2004;23:398-400.

419 Feglo PK, Acheampong DO and Gbedema SY. Prevalence and antibiogram of *Klebsiella* species
420 recovered from clinical samples at the Komfo Anokye teaching hospital in Ghana. *Journal of*
421 *Clinical Research Letters*. 2010;1(2):04-08.

422 Gaiarsa S, Comandatore F, Gaibani P, Corbella M, Dalla, VC, Epis, S, Scaltriti E, Carretto E,
 423 Farina C, Labonia M, Landini MP, Pongolini S, Sambri V, Bandi C, Marone P and Sassera D.
 424 (2015). Genomic epidemiology of *Klebsiella pneumoniae* in Italy and novel insights into the
 425 origin and global evolution of resistance to carbapenem antibiotics. Journal of Antimicrobial
 426 Agents and Chemotherapy. 2015;59(1):386-396.

427 Gastmeier G. Nosocomial infection surveillance and control policies. Journal of Current Opinion
 428 in Infectious Diseases. 2004;17:295-301.

429 Geoffrey AO, Scolastica CK, Joan CC, Ongechi DR, Benard, MM, Godfrey OM, Eliakim MM
 430 and Sabella JK. Isolation, Identification and Characterization of Urinary Tract Infectious Bacteria
 431 and the Effect of Different Antibiotics. Journal of Natural Sciences Research. 2013;3(6):150-
 432 159.

433 Hanan HB, Gwen C, Fong KC, Christine F, Daifallah JA, Maha AA. and Ziad AM. Hospital-
 434 and community-acquired infections: a point prevalence and risk factors survey in a tertiary care
 435 center in Saudi Arabia, International Journal of Infectious Diseases, 2006;10(4):326-333.

436 Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K. and Hryniewicz, W.
 437 Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland.
 438 Journal of Antimicrobial Agents and Chemotherapy, 2001;47(6):773-780.

439 Jemima SA. and Verghese S. Molecular Characterization of Nosocomial CTX-M Type β -
 440 Lactamase Producing *Enterobacteriaceae* from a Tertiary Care Hospital in South India. Indian
 441 Journal of Medical Microbiology. 2008;26(4): 365-368.

442 Karim A, Poirel L, Nagarajan S. and Nordmann P. Plasmid- mediated extended-spectrum beta-
 443 lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1.
 444 Federation of European Microbiological Societies Microbiology Letters. 2001;201:237-241.

445 Khanfar HS, Bindayna KM, Senok AC and Botta GA. Extended spectrum beta-lactamases
 446 (ESBL) in *Escherichia coli* and *Klebsiella pneumoniae*: trends in the hospital and community
 447 settings. Journal of Infection in Developing Countries. 2009;1: 3(4): 295-299.

448 Koenig MS and Truitt JD. Ventilator-Associated Pneumonia: Diagnosis, Treatment and
 449 Prevention. Journal of Clinical Microbiology Reviews. 2006;19(4): 637-657.

450 Kolawale AS, Kolawale OM, Kandaki-Olukemi YT, Babatunde SK, Durowade KA and
 451 Kolawale CF. Prevalence of urinary tract infections among patients attending Dalhatu Araf
 452 Specialist Hospital, Lafia, Nasarawa State, Nigeria. International Journal of Medicine and
 453 Medical Sciences. 2009;1(5):163-167.

454 Li X and Wang HH. Tetracycline resistance associated with commensal bacteria from
 455 representative ready-to-consume deli and restaurant foods. Journal of Food Protection.
 456 2010;73:1841-1848.

457 Lipps G. (2008). Plasmids, Current Research and Future Trends. Horizon Scientific Press, 263.

458 Mehrgan H and Rahbar M. Prevalence of extended-spectrum beta-lactamase-producing
 459 *Escherichia coli* in a tertiary care hospital in Tehran, Iran. International Journal of Antimicrobial
 460 Agents. 2008;31:1471-1451.

461 Newman MJ. Nosocomial and community acquired infections in Korle Bu Teaching Hospital,
462 Accra. West African Journal of Medicine. 2009;28(5):300-303.

463 Nordamann P, Cuzon G and Naas T. The real threat of *Klebsiella pneumonia* carbapenemase-
464 producing bacteria. Journal of Infectious Diseases. 2009;9(4): 228-236.

465 Nwosu IL, Amadi ES, Nwanyanwu CE, Chikwendu CI and Madu CL. The prevalence of
466 extended spectrum beta-lactamases (ESBLs) among *Escherichia coli* and *Klebsiella* species
467 isolates from urinary isolates from Abia state university teaching hospital (ABSUTH) Aba, Abia
468 state, Nigeria. International Journal of Microbiology and Mycology. 2014;2(3):20-28.

469 Nyamogoba H and Obala AA. Nosocomial infections in developing countries: cost effective
470 control and prevention. East African Medical Journal, 2002;79:435-441.

471 Okeke IN, Fayinka ST and Lamikanra A. Antibiotic resistance trends in *Escherichia coli* from
472 apparently healthy Nigerian students (1986-1998). Journal of Emerging Infectious Disease,
473 2000;6:393-396.

474 Okeke IN, Aboderin OA, Byarugaba DK, Ojo, KK and Opintan JA. Growing problem of
475 multidrug-resistant enteric pathogens in Africa. Emerging Infectious Diseases. 2007;13(11):
476 1640-1646.

477 Okonko IO, Soley FA, Amusan TA, Ogun, AA, Ogunnusi, TA and Ejembi J. Incidence of
478 Multi-Drug Resistance (MDR) Organisms in Abeokuta, Southwestern Nigeria. Global Journal of
479 Pharmacology. 2009a;3(2):69-80.

480 Okonko IO, Ijandipe LA, Ilusanya OA, Donbraye-Emmanuel OB, Ejembi J, Udeze AO, Egun,
481 OC, Fowotade A and Nkang AO. Incidence of urinary tract infection (UTI) among pregnant
482 women in Ibadan, South-Western Nigeria. African Journal of Biotechnology. 2009b;8(23): 6649-
483 6657.

484 Olusola A, Akingbade IJ, Ogiogwa IO, Okonko PO, Okerentugba, HC. Innocent-Adiele,
485 Jonathan CN and Charles CO. Plasmid Profile of Isolated *Klebsiella* species in a Tertiary
486 Hospital in Abeokuta, Ogun State, Nigeria. World Applied Sciences Journal, 2013;21(3):371-
487 378.

488 Orhue PO, Igumbor EO, Enweani IB, Esumeh, FI, Ohenhen RE and Igbinosa EO. Antibigram
489 types of *Klebsiella aerogenes* isolated from urinary tract infection (UTI). African Journal of
490 Microbiology Research. 2012;6(20): 4336-4339.

491 Osazuwa F, Mordi RM, Osazuwa E, Taiwo SS, Alli OAT, Ogbolu DO et al. *Klebsiella* has
492 taken lead among uropathogens in University of Benin Teaching Hospital, Benin City, Nigeria-
493 An observation. New York Science Journal. 2010;2(11):47-51.

494 Osundiya OO, Oladele RO and Oduyebo OO. Multiple Antibiotic Resistance (MAR) Indices of
495 *Pseudomonas* and *Klebsiella* species Isolates in Lagos University Teaching Hospital. African
496 Journal of Clinical and Experimental Microbiology. 2013;14(3):164-168.

497 Patel GP and Balk RA. Systemic steroids in severe sepsis and septic shock. American Journal of
498 Respiratory and Critical Care Medicine. 2012;185(2):133-139.

499 Poirel LD, Girlich TN and Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 β -
500 lactamase from *Pseudomonas aeruginosa* and its plasmid and integron-located gene. Journal of
501 Antimicrobial Agents and Chemotherapy. 2004;45(2):447-453.

502 Priamchuk SD, Fursova NK, Abaev IV, Kovalev IN, Shishkova NA, Pecherskikh EI, Korobova
503 OV, Astashkin EI, Pachkunov DM and Kruglov AN. Genetic determinants of antibacterial
504 resistance among nosocomial *Escherichia coli*, *Klebsiella* spp. and *Enterobacter* spp. isolates
505 collected in Russia within 2003-2007. Antibiot. Khimioter Journal. 2010;55(9-10):3-10.

506 Rossello-Urgell J. Nosocomial infection surveillance and control activities in Spain under
507 HELICS and NosoMed programs frame. Journal of Hospital Infection. 2004;56(2):S55-S57.

508 Sachse S, Bresan S, Erhard M, Edel B, Pfister W, Saupe A and Rödel J. Comparison of
509 multilocus sequence typing, RAPD and MALDI-TOF mass spectrometry for typing of β -lactam-
510 resistant *Klebsiella pneumoniae* strains. Diagnostic Microbiology and Infectious Diseases,
511 2014:S0732-8893(14): 00367-00368.

512 Samuel SO, Kayode OO, Musa OI, Nwigwe GC, Aboderin AO, Salami TAT and Taiwo, S. S.
513 Nosocomial infections and the challenges of controlling developing countries. African Journal of
514 Clinical and Experimental Microbiology. 2010;11(2):102-110.

515 Shah RK, Singh YI, Sanjana RK, Chaudhary N and Saldanha D. Study of Extended spectrum
516 beta-lactamases (ESBLs) producing *Klebsiella* species in various clinical specimens: A
517 preliminary report. Journal of College of Medical Sciences-Nepal. 2010;6(3):19-23.

518 Weisenberg SA, Morgan DJ, Espinal-Witter R and Larone DH. Clinical outcomes of patients
519 with *Klebsiella pneumoniae* carbapenemase-producing *Klebsiella pneumoniae* after treatment
520 with imipenem or meropenem. Diagnostic Microbiology and Infectious Disease. 2009;64(2):
521 233-235.

522 World Health Organization. Prevention of hospital-acquired infections, A practical guide.
523 2002:2nd edition.

524 World Health Organization. Antimicrobial resistance: no action today, no cure tomorrow. World
525 Health Day. 2012.

526 World Health Organization. Antimicrobial resistance. Fact sheet No 194. 2013.